Dice Therapeutics to be acquired by Eli Lilly in $2.4 billion deal

David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly announced on Tuesday that it has entered into a strategic deal valued at $2.4 billion to acquire Dice Therapeutics . This strategic move will strengthen Eli Lilly’s treatment portfolio for immune-related diseases. The deal will involve Eli Lilly acquiring Dice Therapeutics at a price …

Read more

FDA staff urges Covid vaccines for fall to focus on XBB variants

Syringe with Covid-19 vaccine against the XBB Variant. Fight against virus Covid-19 Coronavirus, Vaccination and immunization. Undefined Undefined | Istock | Getty Images The U.S. Food and Drug Administration (FDA) staff announced on Monday that the updated Covid boosters for the upcoming fall and winter vaccination campaign should target specific XBB omicron subvariants. In their …

Read more

Possible rewrite: Potential negative impact on drug development due to Medicare price negotiations

David Ricks, CEO of Eli Lilly, expresses concerns over potential harm to drug development caused by Medicare price negotiations aimed at reducing costs for older Americans. Ricks, in an interview on CNBC’s “The Exchange,” stated, “I’m really worried about the harm this will do to new cures and possibilities in medicine.” The provision in focus …

Read more

Support for Illumina-Grail deal grows among Republican lawmakers and state attorneys general

Republican lawmakers, state attorneys general, and various advocacy groups have expressed their support for Illumina’s acquisition of cancer-test developer Grail, while the Federal Trade Commission (FTC) fights to reverse the deal. On Monday, these groups filed 14 amicus briefs urging the U.S. 5th Circuit Court of Appeals to overturn the FTC order that seeks to …

Read more

Seasonal update effectiveness questioned by FDA advisors

A person in Los Angeles, California receives a COVID-19 vaccination dose at Union Station during a free distribution event for those who have received vaccination shots or booster shots. The U.S. Food and Drug Administration’s panel of advisors has expressed doubts about the need for periodic updates to COVID vaccines, as it is uncertain if …

Read more

Omicron subvariant XBB.1.5 should be the focus of Covid shots this autumn.

> XBB.1.5 strain of Covid CFOTO | Future Publishing | Getty Images The U.S. Food and Drug Administration (FDA) has released a recommendation for Covid vaccine manufacturers to develop single-strain shots for the fall that specifically target the omicron subvariant XBB.1.5. This strain is currently the dominant variant of the virus nationwide. In their official …

Read more

Fashion’s Disturbing Runway Trend: The Indisputable Backslide

CNN — As the Fall-Winter 2023 fashion shows come to a close, it is evident that there was a striking absence of plus-size models on the runways of New York, London, Milan, and Paris. This lack of representation is particularly notable in light of the recent introduction of several weight loss medications in the US …

Read more

FDA advisors recommend targeting XBB variant with Covid vaccines this fall.

A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S. Food and Drug Administration’s independent panel of advisors on Thursday recommended updating Covid shots for the fall and winter to target one specific variant – the …

Read more